Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors

American Journal of Health-System Pharmacy

Volumn 65, Issue 10, 2008, Pages 935-940

  Solski, Lauren V ^a   Longyhore, Daniel S ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b WILKES UNIVERSITY   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Clinical studies; Diabetes mellitus; Mechanism of action; Methodology

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; GLUCOSE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; METFORMIN; METOPROLOL; PLACEBO; RAMIPRIL; RESERPINE; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORRELATION ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG EFFICACY; EVALUATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS FUNCTION; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW;

EID: 43949122932     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070388     Document Type: Review

References (43)